Canton Strategic Holdings (CNTN) Share-based Compensation (2020 - 2026)
Canton Strategic Holdings' (CNTN) quarterly Share-based Compensation came in at $32.3 million in Q1 2026, up 14618.45% YoY from N/an in Q1 2025, and up 1951.78% on a QoQ basis from $1.6 million in Q4 2025.
Analysis
Canton Strategic Holdings (CNTN) Share-based Compensation (2020 - 2026) Analysis & Trends
Canton Strategic Holdings (CNTN) has 6 years of Share-based Compensation data on file, last reported at $32.3 million in Q1 2026.
- Quarterly Share-based Compensation rose 14618.45% year-over-year to $32.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $34.6 million (up 4358.39% YoY) and the FY2025 annual result came in at $2.9 million, up 305.15% from the prior year.
- Share-based Compensation rose to $32.3 million in Q1 2026, from $1.6 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $32.3 million in Q1 2026 to a low of $19381.0 in Q1 2022.
- A 5-year average of $2.2 million and a median of $202002.0 in 2022 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2022 — Share-based Compensation tumbled 97.12% — and 2026, when it surged 14618.45%.
- Tracing CNTN's Share-based Compensation over 5 years: stood at $202002.0 in 2022, then tumbled by 50.5% to $100000.0 in 2023, then jumped by 111.1% to $211104.0 in 2024, then jumped by 644.79% to $1.6 million in 2025, then surged by 1951.78% to $32.3 million in 2026.
- The last three Share-based Compensation figures came in at $32.3 million (Q1 2026), $1.6 million (Q4 2025), and $200000.0 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 120.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 277.20 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 137.41 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 86.63 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Canton Strategic Holdings | 493.37 Mn | 493.37 Mn | - | 656,163.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 656,163.00 |
| Mar 31, 2026 | 32.26 Mn |
| Dec 31, 2025 | 1.57 Mn |
| Sep 30, 2025 | 1.21 Mn |
| Jun 30, 2025 | 567,636.00 |
| Mar 31, 2025 | 242,788.00 |
| Dec 31, 2024 | 211,104.00 |
| Sep 30, 2024 | 191,943.00 |
| Jun 30, 2024 | 153,647.00 |
| Mar 31, 2024 | 153,619.00 |
| Dec 31, 2023 | 170,443.00 |
| Sep 30, 2023 | 157,960.00 |
| Jun 30, 2023 | 158,027.00 |
| Mar 31, 2023 | 345,432.00 |
| Dec 31, 2022 | 202,002.00 |
| Sep 30, 2022 | 240,762.00 |
| Jun 30, 2022 | 338,551.00 |
| Mar 31, 2022 | 1.82 Mn |
| Dec 31, 2021 | 6,742.00 |
| Sep 30, 2021 | 4,435.00 |